$247 Million is the total value of Foresite Capital Management II, LLC's 12 reported holdings in Q3 2017. The portfolio turnover from Q2 2017 to Q3 2017 was 69.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AIMT | Sell | Aimmune Therapeutics, Inc. | $94,709,000 | +15.4% | 3,820,462 | -4.3% | 38.39% | +2.1% |
| AERI | Aerie Pharmaceuticals, Inc. | $81,294,000 | -7.5% | 1,672,714 | 0.0% | 32.95% | -18.2% | |
| EPZM | Buy | Epizyme, Inc. | $29,396,000 | +31.1% | 1,543,108 | +3.9% | 11.92% | +16.0% |
| ALDR | Alder BioPharmaceuticals, Inc. | $12,787,000 | +7.0% | 1,043,832 | 0.0% | 5.18% | -5.4% | |
| INSM | New | Insmed Incorporated | $9,363,000 | – | 300,000 | +100.0% | 3.80% | – |
| XLRN | New | Acceleron Pharma Inc. | $9,134,000 | – | 244,756 | +100.0% | 3.70% | – |
| JUNO | New | Juno Therapeutics, Inc. | $4,037,000 | – | 90,000 | +100.0% | 1.64% | – |
| JNCE | Jounce Therapeutics, Inc. | $1,868,000 | +11.1% | 119,912 | 0.0% | 0.76% | -1.8% | |
| DERM | Sell | Dermira, Inc. | $1,583,000 | -59.8% | 58,624 | -56.7% | 0.64% | -64.5% |
| LOXO | New | Loxo Oncology, Inc. | $1,317,000 | – | 14,300 | +100.0% | 0.53% | – |
| OREXQ | Sell | Orexigen Therapeutics, Inc. | $1,109,000 | -36.5% | 523,132 | -13.1% | 0.45% | -43.8% |
| ZFGN | Sell | Zafgen, Inc. | $108,000 | -74.3% | 30,775 | -74.3% | 0.04% | -77.1% |
| ARDX | Exit | Ardelyx, Inc. | $0 | – | -37,500 | -100.0% | -0.09% | – |
| SGMO | Exit | Sangamo Therapeutics, Inc. | $0 | – | -46,000 | -100.0% | -0.19% | – |
| BLCM | Exit | Bellicum Pharmaceuticals, Inc. | $0 | – | -50,559 | -100.0% | -0.27% | – |
| AKBA | Exit | Akebia Therapeutics Inc. | $0 | – | -50,000 | -100.0% | -0.33% | – |
| NSTG | Exit | NanoString Technologies, Inc. | $0 | – | -254,015 | -100.0% | -1.92% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-11-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Epizyme, Inc. | 29 | Q4 2021 | 11.9% |
| Acceleron Pharma Inc. | 24 | Q3 2021 | 4.8% |
| Aerie Pharmaceuticals, Inc. | 22 | Q1 2020 | 40.3% |
| 10x Genomics, Inc. | 17 | Q3 2023 | 100.0% |
| Aimmune Therapeutics, Inc. | 17 | Q3 2019 | 41.0% |
| Alder BioPharmaceuticals, Inc. | 16 | Q3 2019 | 12.6% |
| Zafgen, Inc. | 12 | Q3 2017 | 33.5% |
| BioDelivery Sciences International, Inc. | 12 | Q1 2019 | 3.2% |
| Insmed Incorporated | 11 | Q1 2020 | 13.8% |
| Adaptimmune Therapeutics PLC | 9 | Q4 2018 | 11.3% |
View Foresite Capital Management II, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-12 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-11 |
| 13F-HR | 2021-11-12 |
| 13F-HR | 2021-08-16 |
View Foresite Capital Management II, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.